Summary for ARTG Entry:
LETROZOLE CH letrozole 2.5 mg film-coated tablet blister pack
ARTG entry for
Juno Pharmaceuticals Pty Ltd
Level 2 6 Bond Street,South Yarra, VIC, 3141
ARTG Start Date
Drug Safety Evaluation Branch
Conditions applicable to all therapeutic goods as specified in the document "Standard Conditions Applying to Registered or Listed Therapeutic Goods
Under Section 28 of the Therapeutic Goods Act 1989" effective 1 July 1995.
Conditions applicable to the relevant category and class of therapeutic goods as specified in the document "Standard Conditions Applying to Registered
or Listed Therapeutic Goods Under Section 28 of the Therapeutic Goods Act 1989" effective 1 July 1995.
1. LETROZOLE CH letrozole 2.5 mg film-coated tablet blister pack
Single Medicine Product
See Product Information and Consumer Medicine Information for this product
Treatment of postmenopausal women with hormone receptor positive breast cancer (see "Clinical trials"). The safety and efficacy of neoadjuvant use of
letrozole has not been established. Letrozole is not indicated in hormone receptor negative disease.
Additional Product information
Store below 30
Protect from Moisture
Pack Size/Poison information
(S4) Prescription Only Medicine
Tablet, film coated
Route of Administration
Yellow to dark yellow round, film coated, biconvex tablet engraved with ' L'
on one face and plain on the other
© Commonwealth of Australia.This work is copyright.You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior
written approval from the Commonwealth.Further details can be found at http://www.tga.gov.au/about/website-copyright.htm.
Page 1 of
Produced at 29.11.2017 at 03:13:50 AEDT
This is not an ARTG Certificate document.
The onus is on the reader to verify the current accuracy of the information on the document subsequent to the date shown.
Visit www.tga.gov.au for contact information